PhysioAssist

What PhysioAssist does

PhysioAssist SAS is a French private medical device company founded in 2012 in Aix-en-Provence, France, that has developed and commercializes the Simeox device, a Class 2a medical device for airway clearance in patients with chronic respiratory conditions. The device delivers a proprietary pneumatic vibratory signal during exhalation that liquefies bronchial mucus in under two seconds and transports it from distal airways toward central airways, addressing conditions including cystic fibrosis, COPD, bronchiectasis, and primary ciliary dyskinesia. The underlying technology was developed in partnership with the French National Centre for Scientific Research (CNRS) and the CRCM at Hôpital Nord in Marseille, with an ongoing research program on bronchial mucus rheology; PhysioAssist also maintains a Germany contact office in Miesbach.

The company sells Simeox as its core product through an exclusive country-level distributor network covering approximately 20 markets across Europe, the Middle East, Canada, Australia, and Thailand (including PARI Medical in the UK, Novus Medical in Canada, BMedical in Australia, MedicAir in Italy, HABEL in Austria, and BMEC.asia in Thailand). Revenue is generated via hardware sales of the device and required accessories (tubing, filter, mouthpiece), with pricing handled through a quote-based sales process; Simeox is prescription-based and typically reimbursed through national health systems. The company supports adoption through the free Simeox Academy online training platform for healthcare professionals, active participation in international respiratory conferences (ERS, ECFS), peer-reviewed clinical publications (including a 2023 first RCT in the Children journal), and patient association partnerships such as with Vaincre La Mucoviscidose.

PhysioAssist has obtained CE marking (March 2016), homecare use certification (2019) enabling independent patient use at home, and MDSAP certification (December 2021) covering the US, Canada, Brazil, Japan, and Australia. The company has raised approximately €6 million in a September 2017 Series B led by Mérieux Développement with Turenne Capital; no subsequent funding rounds are disclosed. The company operates with 11–50 employees and is led by Founder & CEO Adrien Mithralal, with Anne Reiser as Chairman and Ulrich Fell as General Manager.

Name

PhysioAssist

Legal name

Physio-Assist SAS

Website

https://physioassist.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

PhysioAssist is a French medical device company that develops and distributes Simeox, a CE-marked Class 2a airway clearance device using proprietary pneumatic vibratory signal technology for patients with cystic fibrosis, COPD, bronchiectasis, and primary ciliary dyskinesia, sold via exclusive distributors in ~20 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Aix-en-provence

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Simeox Medical Device Sales: PhysioAssist generates revenue from the sale of Simeox devices, a Class 2a medical device for airway clearance. The device is sold through exclusive distributor networks in various countries, directly to healthcare institutions, and to patients for home use following healthcare professional prescription and training.
2. Accessories and Consumables: Specific accessories (tubing, filter, and mouthpiece) are required for use with Simeox device. The design of the filter is specific and contributes to the efficacy of the device.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

PhysioAssist designs, manufactures, and sells the Simeox device, a Class 2a medical device that delivers a proprietary pneumatic vibratory signal during exhalation to liquefy and mobilize bronchial mucus from distal airways in patients with chronic respiratory conditions (cystic fibrosis, COPD, bronchiectasis, primary ciliary dyskinesia). The company also operates the Simeox Academy, a free online training platform that educates healthcare professionals on device handling and clinical use. Revenue is generated primarily through hardware sales of the Simeox device and its dedicated consumables (tubing, filter, mouthpiece) via an exclusive international distributor network.

Product overview

PhysioAssist offers a focused product portfolio centered on the Simeox airway clearance medical device. The core offering is the Simeox device, a Class 2a CE-marked medical device that uses proprietary pneumatic signal technology to liquefy and mobilize bronchial mucus in patients with chronic respiratory diseases. This is supported by the Simeox Academy online training platform, which provides healthcare professionals with comprehensive education on device usage and clinical applications. The company operates through a network of exclusive international distributors across Europe, Middle East, Canada, Australia, and Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• Simeox Simeox is a Class 2a medical device that delivers a specific pneumatic vibratory signal during exhalation to liquefy bronchial mucus and transport it from distal to central airways. It is designed for patients with chronic respiratory conditions including cystic fibrosis, COPD, bronchiectasis, and Primary Ciliary Dyskinesia, and can be used in clinical settings or autonomously at home after training by a healthcare professional.
• Simeox Academy Simeox Academy is a free online training platform for healthcare professionals that provides theoretical and practical instruction on the Simeox device, including pathophysiology of mucus clearance, device handling, and clinical practice with real patient demonstrations.

Quantifiable outcome

• In children with cystic fibrosis: Significantly decreased lung obstruction, preserved global ventilation homogeneity especially of distal tract (LCI), increased quality of life (functional physical capacity), safe with no adverse effects
• +4 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered flagship, core and regional.

• Vaincre La MucoviscidoseflagshipStrategic or Co-development Partner · 1 December 2022Partnership with French CF patient association to facilitate access to Simeox device at home without engagement, including financial assistance to patients who wish to access the device.
• Novus Medical Inc.coreChannel Partner/ Reseller/ Distributor · 12 November 2022Exclusive distributor for Canada market, helping respiratory clinicians improve patient lives through access to Simeox device.
• PARI Medical Ltd.coreChannel Partner/ Reseller/ Distributor · 25 May 2020Exclusive distribution agreement for the UK territory. PARI's mission is to improve lives of those affected by respiratory diseases through their portfolio of innovative products and services.
• CNRS (Centre National de la Recherche Scientifique)coreStrategic or Co-development PartnerResearch partnership for the study of bronchial mucus and development of pneumatic vibratory signal technology present in Simeox device. Collaboration with CRCM Hôpital Nord Marseille.
• CRCM Hôpital Nord MarseillecoreStrategic or Co-development PartnerResources and Competences Center for Cystic Fibrosis collaborated with PhysioAssist and CNRS on airway clearance research and Simeox technology development.
• BMEC.asiaregionalChannel Partner/ Reseller/ DistributorDistribution partner for Thailand market, led by Medha Namjoshi.

Scale indicators3 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• PARI Medical Holding: PARI is both an exclusive UK distributor of Simeox and a direct competitor with its own airway clearance portfolio including the PARI O-PEP and eFlow respiratory nebulizer systems. Highly comparable as both a channel partner and a competing device maker in the same therapeutic niche.
• Trudell Medical International (Monaghan Medical): Makes the Acapella and Aerobika oscillating positive expiratory pressure (PEP) devices used for airway clearance in CF, COPD, and bronchiectasis — direct therapeutic alternatives to Simeox with overlapping patient populations and prescriber base (respiratory therapists and pulmonologists).
• Vyaire Medical: Vyaire (formerly CareFusion/BD respiratory) markets The Vest and MetaNeb systems for high-frequency chest wall oscillation (HFCWO) and continuous high-frequency oscillation (CHFO) airway clearance. Most established competitor in the institutional airway clearance market.

Broad incumbents

• Philips Respironics: Broad incumbent in respiratory care with nebulizers, ventilators, and airway clearance adjuncts. While not focused exclusively on mucus clearance, Philips competes for hospital respiratory therapy budgets and prescriber mindshare with Simeox.
• ResMed: Global leader in respiratory and sleep medicine devices including ventilation and COPD management solutions. ResMed's commercial scale, direct-to-clinician sales channels, and reimbursement expertise represent both a competitive threat and a potential strategic acquirer profile for PhysioAssist.
• Hillrom (now part of Baxter): Hillrom's The Vest System is one of the most widely adopted HFCWO airway clearance devices globally. As part of Baxter, the combined entity competes head-to-head with Simeox in CF centers and respiratory clinics worldwide.
• Drägerwerk: German medical device incumbent producing ventilators, anesthesia equipment, and respiratory therapy devices. Operates in the same hospital respiratory care channel as PhysioAssist and competes for ICU/pulmonology capex.
• Fisher & Paykel Healthcare: New Zealand-based respiratory care company with strong presence in humidification, CPAP, and COPD-adjacent devices. Comparable as a respiratory-focused medical device company with international distributor networks and recurring consumables.
• Smiths Medical: Major medical device company with respiratory care portfolio including airway management and humidification products. Comparable as a broad respiratory device incumbent competing for hospital and homecare channels relevant to Simeox.

Emerging players

• Vortran Medical Technology: Smaller medical device maker focused on disposable respiratory products including percussionators and oxygen delivery. Comparable niche-scale competitor in the respiratory therapy space with overlapping clinical use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/physioassist
• Facebookfacebook.com/physioassist
• LinkedInlinkedin.com/company/physioassist
• Instagraminstagram.com/physioassist1

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhysioAssist